MTHFR Gene Mutations: What They Are and Why So Many People Have Them

Few genetic variants have generated as much discussion — and as much confusion — in health and wellness circles as MTHFR. It appears in conversations about mental health, pregnancy, cardiovascular risk, fatigue, chronic illness, and detoxification. Functional medicine practitioners frequently test for it. Online communities discuss it extensively. People discover they have an “MTHFR mutation” and wonder whether it explains years of unexplained symptoms, or whether it means anything at all.

The reality is somewhere between the alarm some people feel upon discovering an MTHFR variant and the dismissiveness with which some mainstream medical settings treat it. MTHFR variants are genuinely common — far more common than most genetic variants discussed in health contexts — and they do have real biological effects. But those effects are considerably more nuanced than the shorthand “MTHFR mutation” suggests, and understanding them clearly matters both for knowing when to take action and for avoiding unnecessary worry.

Here is a thorough, plain-English look at what MTHFR actually is, what the variants found in DNA testing actually do, why they are so prevalent, and what the science actually supports in terms of health implications and practical responses.

What the MTHFR Gene Does and Why It Matters

MTHFR stands for methylenetetrahydrofolate reductase — an enzyme that performs a specific and essential step in folate metabolism. To understand why this matters, it helps to trace the pathway the enzyme sits within.

Folate — vitamin B9 — enters the body through food (leafy greens, legumes, liver) or supplementation (folic acid, the synthetic form). In the body, folate is converted through a series of steps into various active forms that serve different biological purposes. The MTHFR enzyme specifically converts 5,10-methylenetetrahydrofolate into 5-methyltetrahydrofolate — commonly called methylfolate, or 5-MTHF. This methylfolate form serves two critical downstream functions: it donates a methyl group to convert homocysteine back into methionine, and that methionine is subsequently used to generate S-adenosylmethionine (SAM) — the body’s universal methyl donor.

SAM participates in hundreds of methylation reactions throughout the body, including the methylation of DNA, the synthesis and regulation of neurotransmitters, the production of myelin (the protective sheath around nerve fibers), the detoxification of certain compounds in the liver, and the regulation of gene expression through epigenetic mechanisms. This is why MTHFR sits at such a central position in cellular biochemistry — it’s not just a folate metabolism enzyme, it’s the gateway to the methylation cycle that underlies an enormous range of biological processes.

The Two Main MTHFR Variants

Two variants in the MTHFR gene are most commonly tested and most clinically studied: C677T and A1298C. Both are single nucleotide polymorphisms — single-letter changes in the DNA sequence — and both produce an enzyme with reduced activity compared to the standard version. They differ in where they occur within the gene and in the magnitude and nature of their effects.

C677T (rs1801133) results in an amino acid change from alanine to valine at position 677 of the protein. This substitution makes the enzyme thermolabile — more sensitive to heat — and reduces its activity. People who carry one copy of the C677T variant (heterozygous) have roughly 65 percent of normal MTHFR enzyme activity. People who carry two copies (homozygous, sometimes written as TT) have approximately 30 percent of normal activity. This means their conversion of dietary folate forms into the active methylfolate is substantially less efficient.

A1298C (rs1801131) results in a different amino acid change — glutamate to alanine at position 1298 — and produces a milder reduction in enzyme activity. Homozygous A1298C carriers have roughly 60 percent of normal activity. The effect of carrying one copy of each variant — compound heterozygous, or C677T/A1298C — is intermediate between the two homozygous states and is associated with meaningfully reduced methylation capacity.

Why MTHFR Variants Are So Remarkably Common

One of the most striking facts about MTHFR is just how common these variants are. The C677T variant is carried by approximately 10 to 15 percent of people of European and Asian ancestry in the homozygous TT form, with heterozygous rates considerably higher. Rates vary substantially by ancestry — the TT genotype is found in roughly 25 percent of Hispanic populations in some studies, and rates differ across European, African, and Asian ancestry groups as well. When you add together all the people carrying at least one copy of either C677T or A1298C, the majority of the human population carries at least one MTHFR variant of some kind.

This prevalence raises an interesting evolutionary question: if MTHFR variants reduce enzyme activity, why haven’t they been selected against over human history? The answer likely lies in two related factors. First, in environments with abundant dietary folate from plant foods, even reduced MTHFR activity may be sufficient to maintain adequate methylation — the enzyme only becomes a significant bottleneck when folate intake is consistently low. Second, some research has suggested that reduced MTHFR activity may have offered protective advantages under specific historical conditions — including, potentially, reduced susceptibility to certain infections that exploit the folate pathway — creating conditions where the variants were maintained or even mildly favored in some populations.

The practical implication is that having an MTHFR variant is not an unusual medical finding — it’s a common genetic difference that describes a meaningful fraction of the population. The relevant question is not whether you have a variant, but what that variant means for your specific health picture given your diet, lifestyle, and any symptoms or conditions you’re managing.

What MTHFR Variants Actually Affect — and How Much

Because MTHFR sits at the center of the methylation cycle, its variants have the potential to influence a wide range of biological processes. The research on each of these areas varies in quality and consistency, and it’s worth being honest about where the evidence is robust and where it’s more preliminary.

Homocysteine Levels

The most consistently documented effect of MTHFR C677T homozygosity is elevated blood homocysteine. When the MTHFR enzyme is less active, the conversion of homocysteine to methionine slows, and homocysteine accumulates. Homozygous TT individuals have been found in multiple large studies to have homocysteine levels roughly 25 percent higher on average than those with the CC genotype, particularly when folate intake is inadequate. Elevated homocysteine is an independent risk factor for cardiovascular disease, stroke, and blood clot formation, and is associated with adverse pregnancy outcomes including neural tube defects. Adequate folate intake — particularly in the methylfolate form that bypasses the MTHFR conversion step — substantially reduces homocysteine in TT individuals, which is why this is one of the most actionable MTHFR findings.

Pregnancy and Neural Tube Defects

The connection between folate and neural tube defects — birth defects affecting the brain and spinal cord — is one of the most firmly established findings in nutritional epidemiology, and MTHFR variants are part of this story. Both maternal and fetal MTHFR genotype influence risk. Mothers with reduced MTHFR function who have inadequate folate intake are at elevated risk of having a child with a neural tube defect, independent of folic acid supplementation with standard folic acid — since folic acid requires MTHFR conversion to become active. This is a specific situation where the form of supplementation matters: methylfolate rather than folic acid is increasingly recommended for women with MTHFR variants who are pregnant or planning pregnancy, though this should be discussed with an obstetric provider.

Methylation Capacity and Its Downstream Effects

Reduced methylation capacity from MTHFR variants has been proposed as a contributor to a broad range of conditions — depression, anxiety, ADHD, chronic fatigue, and others — through downstream effects on neurotransmitter synthesis, DNA methylation, and myelin maintenance. The evidence here is considerably more mixed than for homocysteine and cardiovascular risk. Some research supports associations between MTHFR variants and mood disorders, but the effect sizes tend to be modest and the relationship is heavily mediated by folate status. When adequate methylfolate is available, the downstream effects on neurotransmitter pathways appear to be largely compensated for in most people.

That said, for individuals who are both homozygous TT for C677T and consuming a diet low in natural folate — a combination that substantially impairs methylation cycle throughput — the downstream effects on neurotransmitter synthesis and mood regulation may be more pronounced. This is an area where clinical experience often outpaces the available controlled research, and where individual response to methylfolate supplementation varies considerably.

Detoxification and Drug Metabolism

As discussed in the detoxification article earlier in this series, MTHFR affects the availability of methyl donors for Phase II liver detoxification reactions and glutathione synthesis. For people with both significant MTHFR variants and other detoxification gene variants — such as GSTM1 null or COMT slow variants — the combined effect on detoxification capacity may be more meaningful than any single variant in isolation. This is one of the arguments for analyzing the full pathway context rather than any single gene in isolation.

What to Actually Do If You Have an MTHFR Variant

The most important thing to do with an MTHFR result is resist the urge to either catastrophize or dismiss it. Having a C677T or A1298C variant is common, and for most people with adequate dietary folate and a generally healthy lifestyle, the variant’s effects are modest and well-managed through basic nutritional attention.

The most evidence-based practical steps depend on which variant you carry and in what combination. For heterozygous C677T carriers, the priority is ensuring good dietary folate intake from natural food sources — dark leafy greens, legumes, liver — and considering a methylfolate-containing multivitamin rather than one relying solely on folic acid. For homozygous TT carriers, the case for specifically choosing the methylfolate form of supplementation is stronger, as the conversion step MTHFR performs is substantially impaired and supplementing the end product directly is more reliable than relying on a reduced-efficiency enzyme to convert a precursor. Checking homocysteine levels through a blood test is reasonable and provides direct evidence of whether the methylation cycle is functioning adequately regardless of variant status.

For women who are pregnant or planning pregnancy, a conversation with an obstetric provider specifically about MTHFR status and folate supplementation form is worth having. For people with symptoms they suspect may be related to methylation — fatigue, mood instability, cognitive fogginess, medication sensitivity — a thorough evaluation by a clinician familiar with nutrigenomics can help determine how much of the picture MTHFR is contributing to versus other factors.

A DNA report that analyzes the full methylation pathway — including MTHFR alongside COMT, MTR, MTRR, and other genes involved in the methylation cycle — provides considerably more context than MTHFR in isolation. The methylation cycle is an interlocking system, and which specific steps are most rate-limiting for an individual depends on the full complement of variants they carry, not just their MTHFR status alone.

Frequently Asked Questions

Is an MTHFR variant the same as a mutation?

The word “mutation” implies something has gone wrong, which is why “variant” is more accurate for something this common. C677T and A1298C are single nucleotide polymorphisms — normal genetic variations found across the human population at high frequency. Calling them mutations is technically defensible in the strict molecular sense, but it creates a misleading impression of rarity and abnormality for variants carried by the majority of humans in at least one copy.

Should everyone be tested for MTHFR?

Routine population screening for MTHFR variants is not currently recommended by major medical organizations, in part because the variants are so common and the management response — adequate folate, preferably as methylfolate — is the same regardless of whether you know your genotype. Testing becomes most clinically meaningful for people with consistently elevated homocysteine, a personal or family history of cardiovascular events or blood clots, a history of pregnancy complications including neural tube defects, or symptoms suggesting significant methylation impairment. DNA health testing that includes MTHFR can provide this information in a broader genetic context.

Can I eat my way out of an MTHFR variant?

Diet is genuinely one of the most powerful levers available. Because reduced MTHFR activity is a conversion bottleneck — not a complete absence of function — providing the end product directly through dietary methylfolate (abundant in dark leafy greens and liver) or methylfolate supplementation largely compensates for the reduced conversion step. Research consistently shows that adequate folate intake normalizes homocysteine even in homozygous TT individuals, which addresses the most well-documented cardiovascular risk associated with the variant.

Why do some people feel dramatically better after starting methylfolate, while others notice nothing?

Individual response to methylfolate supplementation varies because MTHFR is only one variable in a complex system. People who feel significantly better often had a meaningful functional folate deficiency — even with seemingly adequate dietary intake — and the methylfolate addressed a real bottleneck in their methylation cycle. People who notice little effect either had adequate methylation to begin with, have rate-limiting variants elsewhere in the cycle that methylfolate doesn’t address, or — in some cases — may find that excess methylfolate drives side effects including anxiety or overstimulation, particularly in people who are sensitive to rapid shifts in methyl group availability.

Does MTHFR affect medication response?

Yes, in some cases. MTHFR variants affect the metabolism of methotrexate — a medication used for rheumatoid arthritis and certain cancers that works precisely by inhibiting the folate pathway — making carriers of some variants more susceptible to methotrexate toxicity. MTHFR also influences neurotransmitter synthesis pathways relevant to the effectiveness of certain psychiatric medications. More broadly, reduced methylation capacity can affect the methylation-dependent Phase II metabolism of some drugs. This is worth mentioning to prescribers if you carry significant MTHFR variants and are starting new medications in relevant drug classes.